MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Indomethacin sodium hydrate

CAS No. : 74252-25-8

MCE 站：Indomethacin sodium hydrate

产品活性：Indomethacin sodium hydrate (Indometacin sodium hydrate) 是一种有效的，可透过血脑屏障的，非选择性的 COX1 和 COX2 抑制剂，在 CHO 细胞中，对人 COX-1 和 COX-2 的 IC₅₀ 值分别为 18 nM 和 26 nM。Indomethacin sodium hydrate 通过干扰溶酶体的正常功能来破坏自噬流 (autophagic flux)。

研究领域：Immunology/Inflammation  |  Autophagy

作用靶点：COX  |  Autophagy

In Vitro: Indomethacin is a potent and nonselective inhibitor of COX1 and COX2, with IC₅₀s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells. Indomethacin inhibits lipopolysaccharide (LPS)-induced PGE2 production (COX-2) in a human whole blood assay with a potency (IC₅₀=0.68±0.17?μM), and suppresses coagulation-induced TXB2 production (COX-1) (IC₅₀=0.19±0.02?μM). Indomethacin blocks COX-1 with an IC₅₀ of 20±1?nM in U937 cell microsomes at a low arachidonic acid concentration (0.1?μM).

In Vivo: Indomethacin dose-dependently inhibits both the carrageenan-induced rat paw oedema (ED₅₀, 2.0?mg/kg), hyperalgesia (ED₅₀, 1.5?mg/kg), and is also effective at reversing LPS-induced pyrexia in rats (ED₅₀, 1.1?mg/kg). Indomethacin (2.5 mg/kg, i.p) decreases the number of NeuN⁺ cells in the animals at 8 days after ET-1 injection. Indomethacin also reduces microglia/macrophage activation at 14 days. Indomethacin significantly increases the number of SVZ DCX⁺ cells/field at 14 days post stroke. Indomethacin (22.9 mg/kg, p.o.) produces 8 to 10 linear mucosal lesions extended from the fundic to pyloric area of stomach wall.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  CNS-Penetrant Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Acetaminophen  |  Indomethacin  |  Celecoxib  |  Aspirin  |  Ibuprofen  |  Catechin  |  NS-398  |  Diclofenac  |  20(S)-Ginsenoside Rg3  |  Naproxen  |  (-)-Epicatechin  |  Gallic acid  |  Xanthohumol  |  Sulindac  |  SC-560  |  Carprofen  |  Salicylic acid  |  Meloxicam  |  Rutaecarpine  |  Rebamipide  |  Iguratimod  |  Flufenamic acid  |  Fenofibric acid  |  Isoorientin  |  Nabumetone  |  Neochlorogenic acid  |  Piroxicam  |  Rofecoxib

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。